Liraglutide

Liraglutide, a novel hypoglycemic agent, exerts its glucose-lowering effects by activating AMP-activated protein kinase (AMPK), which in turn enhances insulin sensitivity in target tissues. Beyond its robust hypoglycemic action, this agent offers multifaceted clinical benefits including weight reduction, blood pressure lowering, and favorable modulation of lipid profiles.

As a selective human glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide mediates weight loss through multiple synergistic mechanisms: it slows gastric emptying to prolong satiety and reduce caloric intake, blunts central appetite signaling in the brain to curb food cravings, and elevates systemic energy expenditure to promote fat catabolism. For glycemic control, it inhibits excessive hepatic gluconeogenesis and stimulates glucose-dependent insulin secretion from pancreatic β-cells, ensuring precise blood sugar regulation without an increased risk of hypoglycemia. Additionally, liraglutide confers notable cardioprotective effects and renoprotective properties, making it a valuable therapeutic option for patients with comorbid cardiovascular and renal risks alongside their metabolic disorders.